Atrial fibrillation. Chronic atrial fibrillation
Conditions
Interventions
Intervention 1: Intervention group: After random allocation, 165 patients with atrial fibrillation will take one tablet of Rivaroxaban (Xalerban) 20 mg orally, produced by Abidi pharmaceutical compan
Sponsors
Vice-Chancellor For Research and Technology of Guilan University of Medical Sciences
Dr. Abidi Pharmaceutical Company
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: Being over 50 years old Patients with Atrial fibrillation CHAD2S2 Vasc Score more than 1
Exclusion criteria
Exclusion criteria: Patient's dissatisfaction with the study Wolff Parkinson White Syndrome Allergic to any of the drugs Rivaroxaban (Xalerban) and warfarin Abnormal Creatinine level Thrombocytopenia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bleeding. Timepoint: All patients will be followed up by researchers every 15 days in the first month and then every month for 6 month. Method of measurement: Measurement of coagulation factors and hemoglobin level by blood test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in liver's enzymes. Timepoint: All patients will be followed up by researchers every 15 days in the first month and then every month for 6 month. Method of measurement: Measurement of liver's enzymes (SGOT, SGPT) by blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Jalal Kheirkhah
Healthy Heart Research Center of Guilan University of Medical Sciences
Outcome results
None listed